DOCSLIB.ORG

Pharmaceutical Appendix to the Tariff Schedule 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceutical Appendix to the Tariff Schedule 2 Harmonized Tariff Schedule of the United States (2007) Prelim. – Eff. 1/1/07 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) Prelim. – Eff. 1/1/07 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9 ACOXATRINE 748-44-7 ACAPRAZINE 55485-20-6 ACREOZAST 123548-56-1 ACARBOSE 56180-94-0 ACRIDOREX 47487-22-9 ACEBROCHOL 514-50-1 ACRIFLAVINIUM CHLORIDE 8063-24-9 ACEBURIC ACID 26976-72-7 ACRIHELLIN 67696-82-6 ACEBUTOLOL 37517-30-9 ACRISORCIN 7527-91-5 ACECAINIDE 32795-44-1 ACRIVASTINE 87848-99-5 ACECARBROMAL 77-66-7 ACROCINONIDE 28971-58-6 ACECLIDINE 827-61-2 ACRONINE 7008-42-6 ACECLOFENAC 89796-99-6 ACTAGARDIN ACEDAPSONE 77-46-3 ACTAPLANIN 37305-75-2 ACEDIASULFONE SODIUM 127-60-6 ACTARIT 18699-02-0 ACEDOBEN 556-08-1 ACTINOQUINOL 15301-40-3 ACEFLURANOL 80595-73-9 ACTISOMIDE 96914-39-5 ACEFURTIAMINE 10072-48-7 ACTODIGIN 36983-69-4 ACEFYLLINE CLOFIBROL 70788-27-1 ADAFENOXATE 82168-26-1 ACEFYLLINE PIPERAZINE 18428-63-2 ADALIMUMABUM 331731-18-1 ACEGLATONE 642-83-1 ADAMEXINE 54785-02-3 ACEGLUTAMIDE 2490-97-3 ADAPALENE 106685-40-9 ACEMANNAN 110042-95-0 ADAPROLOL 101479-70-3 ACEMETACIN 53164-05-9 ADARGILEUKINUM ALFA 250710-65-7 ACENEURAMIC ACID 131-48-6 ADATANSERIN 127266-56-2 ACENOCOUMAROL 152-72-7 ADECATUMUMABUM 503605-66-1 ACEPERONE 807-31-8 ADEFOVIR 106941-25-7 ACEPROMAZINE 61-00-7 ADEKALANTUM 227940-00-3 ACEPROMETAZINE 13461-01-3 ADELMIDROL 1675-66-7 ACEQUINOLINE 42465-20-3 ADEMETIONINE 17176-17-9 ACESULFAME 33665-90-6 ADENOSINE PHOSPHATE 61-19-8 ACETAMINOSALOL 118-57-0 ADIBENDAN 100510-33-6 ACETARSOL 97-44-9 ADICILLIN 525-94-0 ACETAZOLAMIDE 59-66-5 ADIMOLOL 78459-19-5 ACETERGAMINE 3031-48-9 ADINAZOLAM 37115-32-5 ACETIAMINE 299-89-8 ADIPHENINE 64-95-9 ACETIROMATE 2260-08-4 ADIPIODONE 606-17-7 ACETOHEXAMIDE 968-81-0 ADITEREN 56066-19-4 ACETOHYDROXAMIC ACID 546-88-3 ADITOPRIM 56066-63-8 ACETOPHENAZINE 2751-68-0 ADOSOPINE 88124-26-9 ACETORPHINE 25333-77-1 ADOZELESIN 110314-48-2 ACETRYPTINE 3551-18-6 ADRAFINIL 63547-13-7 ACETYLCHOLINE CHLORIDE 60-31-1 ADRENALONE 99-45-6 ACETYLCYSTEINE 616-91-1 ADROGOLIDUM 171752-56-0 ACETYLDIGITOXIN 1111-39-3 AFALANINE 2901-75-9 ACETYLLEUCINE 99-15-0 AFELETECANUM 215604-75-4 ACETYLMETHADOL 509-74-0 AFELIMOMAB 156227-98-4 ACEVALTRATE 25161-41-5 AFLOQUALONE 56287-74-2 ACEXAMIC ACID 57-08-9 AFOVIRSEN 151356-08-0 ACICLOVIR 59277-89-3 AFUROLOL 65776-67-2 ACIDUM ARUNDICUM 185517-21-9 AGALSIDASUM ALFA 104138-64-9 ACIDUM CALOXETICUM 135306-78-4 AGALSIDASUM BETA 104138-64-9 ACIDUM CARGLUMICUM 1188-38-1 AGANODINE 86696-87-9 ACIDUM GADOCOLETICUM 280776-87-6 AGLEPRISTONE 124478-60-0 AGOMELATINE 138112-76-2 ALNESPIRONE 138298-79-0 AKLOMIDE 3011-89-0 ALNIDITAN 152317-89-0 ALACEPRIL 74258-86-9 ALONACIC 105292-70-4 ALAFOSFALIN 60668-24-8 ALONIMID 2897-83-8 ALAGEBRIUM CHLORIDUM 341028-37-3 ALORACETAM 119610-26-3 ALAMIFOVIRUM 193681-12-8 ALOSETRON 122852-42-0 ALANINE 56-41-7 ALOVUDINE 25526-93-6 ALANOSINE 5854-93-3 ALOXIPRIN 9014-67-9 ALAPROCLATE 60719-82-6 ALOXISTATIN 88321-09-9 ALATROFLOXACIN 157182-32-6 ALOZAFONE 65899-72-1 ALAZANINE TRICLOFENATE 5779-59-9 ALPERTINE 27076-46-6 ALBACONAZOLUM 187949-02-6 ALPHACETYLMETHADOL 17199-58-5 ALBENDAZOLE 54965-21-8 ALPHAMEPRODINE 468-51-9 ALBENDAZOLE OXIDE 54029-12-8 ALPHAMETHADOL 17199-54-1 ALBIFYLLINE 107767-55-5 ALPHAPRODINE 77-20-3 ALBUTOIN 830-89-7 ALPIDEM 82626-01-5 ALCLOFENAC 22131-79-9 ALPIROPRIDE 81982-32-3 ALCLOMETASONE 67452-97-5 ALPRAFENONE 124316-02-5 ALCLOXA 1317-25-5 ALPRAZOLAM 28981-97-7 ALCURONIUM CHLORIDE 15180-03-7 ALPRENOLOL 13655-52-2 ALDESULFONE SODIUM 144-75-2 ALPROSTADIL 745-65-3 ALDIOXA 5579-81-7 ALRESTATIN 51411-04-2 ALDOSTERONE 52-39-1 ALSACTIDE 34765-96-3 ALEFACEPTUM 222535-22-0 ALTANSERIN 76330-71-7 ALEMCINALUM 150785-53-8 ALTAPIZONE 93277-96-4 ALEMTUZUMABUM 216503-57-0 ALTECONAZOLE 93479-96-0 ALENDRONIC ACID 66376-36-1 ALTEPLASE 105857-23-6 ALENTEMOL 112891-97-1 ALTINICLINUM 179120-92-4 ALEPRIDE 66564-15-6 ALTIZIDE 5588-16-9 ALESTRAMUSTINE 139402-18-9 ALTOQUALINE 121029-11-6 ALEXIDINE 22573-93-9 ALTRENOGEST 850-52-2 ALEXITOL SODIUM 66813-51-2 ALTRETAMINE 645-05-6 ALFACALCIDOL 41294-56-8 ALTUMOMAB 156586-92-4 ALFADEX 10016-20-3 ALUMINIUM CLOFIBRATE 24818-79-9 ALFADOLONE 14107-37-0 ALUSULF 61115-28-4 ALFAPROSTOL 74176-31-1 ALVAMELINUM 120241-31-8 ALFATRADIOLUM 57-91-0 ALVERINE 150-59-4 ALFAXALONE 23930-19-0 ALVIMOPANUM 156053-89-3 ALFENTANIL 71195-58-9 ALVIRCEPT SUDOTOX 137487-62-8 ALFETAMINE 4255-23-6 ALVOCIDIBUM 146426-40-6 ALFIMEPRASUM 259074-76-5 AMADINONE 30781-27-2 ALFUZOSIN 81403-80-7 AMAFOLONE 50588-47-1 ALGELDRATE 1330-44-5 AMANOZINE 537-17-7 ALGESTONE 595-77-7 AMANTADINE 768-94-5 ALGLUCERASE 143003-46-7 AMANTANIUM BROMIDE 58158-77-3 ALGLUCOSIDASUM ALFA 420784-05-0 AMANTOCILLIN 10004-67-8 ALIBENDOL 26750-81-2 AMBAMUSTINE 85754-59-2 ALICAFORSENUM 185229-68-9 AMBASILIDE 83991-25-7 ALICONAZOLE 63824-12-4 AMBAZONE 539-21-9 ALIFEDRINE 78756-61-3 AMBENONIUM CHLORIDE 115-79-7 ALIFLURANE 56689-41-9 AMBENOXAN 2455-84-7 ALILUSEMUM 144506-11-6 AMBICROMIL 58805-38-2 ALIMADOL 52742-40-2 AMBOMYCIN 1402-81-9 ALIMEMAZINE 84-96-8 AMBRISENTANUM 177036-94-1 ALINASTINE 154541-72-7 AMBROXOL 18683-91-5 ALINIDINE 33178-86-8 AMBRUTICIN 58857-02-6 ALIPAMIDE 3184-59-6 AMBUCAINE 119-29-9 ALISKIRENUM 173334-57-1 AMBUCETAMIDE 519-88-0 ALITRETINOINUM 3/9/00 AMBUSIDE 3754-19-6 ALIZAPRIDE 59338-93-1 AMCINAFAL 3924-70-7 ALLETORPHINE 23758-80-7 AMCINAFIDE 7332-27-6 ALLOBARBITAL 52-43-7 AMCINONIDE 51022-69-6 ALLOCLAMIDE 5486-77-1 AMDOXOVIRUM 145514-04-1 ALLOCUPREIDE SODIUM 5965-40-2 AMEBUCORT 83625-35-8 ALLOMETHADIONE 526-35-2 AMEDALIN 22136-26-1 ALLOPURINOL 315-30-0 AMEDIPLASUM 151912-11-7 ALLYLESTRENOL 432-60-0 AMELOMETASONE 123013-22-9 ALLYLPRODINE 25384-17-2 AMELTOLIDE 787-93-9 ALLYLTHIOUREA 109-57-9 AMELUBANTUM 346735-24-8 ALMADRATE SULFATE 60239-66-9 AMESERGIDE 121588-75-8 ALMAGATE 66827-12-1 AMETANTRONE 64862-96-0 ALMAGODRATE AMEZEPINE 60575-32-8 ALMASILATE 71205-22-6 AMEZINIUM METILSULFATE 30578-37-1 ALMECILLIN 87-09-2 AMFEBUTAMONE 34911-55-2 ALMESTRONE 10448-96-1 AMFECLORAL 5581-35-1 ALMINOPROFEN 39718-89-3 AMFENAC 51579-82-9 ALMITRINE 27469-53-0 AMFEPENTOREX 15686-27-8 ALMOKALANT 123955-10-2 AMFEPRAMONE 90-84-6 ALMOTRIPTAN 154323-57-6 AMFETAMINE 300-62-9 ALMOXATONE 84145-89-1 AMFETAMINIL 17590-01-1 ALMURTIDE 61136-12-7 AMFLUTIZOLE 82114-19-0 Harmonized Tariff Schedule of the United States (2007) Prelim. – Eff. 1/1/07 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 4 AMFOMYCIN 1402-82-0 AMPRENAVIRUM 161814-49-9 AMFONELIC ACID 15180-02-6 AMPROLIUM 121-25-5 AMICARBALIDE 3459-96-9 AMPYRIMINE 5587-93-9 AMICIBONE 23271-63-8 AMPYZINE 5214-29-9 AMICYCLINE 5874-95-3 AMQUINATE 17230-85-2 AMIDANTEL 49745-00-8 AMRINONE 60719-84-8 AMIDAPSONE 3569-77-5 AMRUBICIN 110267-81-7 AMIDEFRINE MESILATE 1421-68-7 AMSACRINE 51264-14-3 AMIFLAMINE 77518-07-1 AMTOLMETIN GUACIL 87344-06-7 AMIFLOVERINE 54063-24-0 AMYLMETACRESOL 1300-94-3 AMIFLOXACIN 86393-37-5 ANAGESTONE 2740-52-5 AMIFOSTINE 20537-88-6 ANAGRELIDE 68475-42-3 AMIGLUMIDUM 119363-62-1 ANAKINRA 143090-92-0 AMIKACIN 37517-28-5 ANARITIDE 95896-08-5 AMIKHELLINE 4439-67-2 ANASTROZOLE 120511-73-1 AMILORIDE 2609-46-3 ANATIBANTUM 209733-45-9 AMINDOCATE 31386-24-0 ANATUMOMABUM MAFENATOXUM (NONE) AMINEPTINE 57574-09-1 ANAXIRONE 77658-97-0 AMINITROZOLE 140-40-9 ANAZOCINE 15378-99-1 AMINOACRIDINE 90-45-9 ANAZOLENE SODIUM 3861-73-2 AMINOCAPROIC ACID 60-32-2 ANCAROLOL 75748-50-4 AMINOETHYL NITRATE 646-02-6 ANCESTIMUM 163545-26-4 AMINOGLUTETHIMIDE 125-84-8 ANCITABINE 31698-14-3 AMINOMETRADINE 642-44-4 ANCRIVIROCUM 370893-06-4 AMINOPHENAZONE 58-15-1 ANCROD 9046-56-4 AMINOPHENAZONE CYCLAMATE 747-30-8 ANDOLAST 132640-22-3 AMINOPHYLLINE 317-34-0 ANDROSTANOLONE 521-18-6 AMINOPROMAZINE 58-37-7 ANECORTAVUM 7753-60-8 AMINOPTERIN SODIUM 58602-66-7 ANGIOTENSIN II 4474-91-3 AMINOQUINOL 10023-54-8 ANGIOTENSINAMIDE 53-73-6 AMINOQUINURIDE 3811-56-1 ANIDOXIME 34297-34-2 AMINOREX 2207-50-3 ANIDULAFUNGINUM 166663-25-8 AMINOTHIAZOLE 96-50-4 ANILAMATE 5591-49-1 AMINOXYTRIPHENE 5585-64-8 ANILERIDINE 144-14-9 AMIODARONE 1951-25-3 ANILOPAM 53716-46-4 AMIPERONE 1580-71-8 ANIPAMIL 83200-10-6 AMIPHENAZOLE 490-55-1 ANIRACETAM 72432-10-1 AMIPIZONE 69635-63-8 ANIROLAC 66635-85-6 AMIPRILOSE 56824-20-5 ANISACRIL 5129-14-6 AMIQUINSIN 13425-92-8 ANISINDIONE 117-37-3
Load more

Recommended publications
  • United States Patent [19] [11] Patent Number: 6,149,923 Shirahase Et Al
    US006149923A United States Patent [19] [11] Patent Number: 6,149,923 Shirahase et al. [45] Date of Patent: Nov. 21, 2000 [54] ANTIRHEUMATIC AGENT OTHER PUBLICATIONS [75] Inventors: Hiroaki Shirahase, Nagaokakyo; Yoshimi et al Importance of Hydrolysis of Amino Acid Akihisa Yoshimi, Takatsuki; Fumio Moiety in Water—Soluble Prodrugs of Disodium Cromogly Fukata, Osaka; Hideki Okunishi; Yuta cate for Increased Oral Bioavailability 1992 J. Pharmaco Kobayashi, both of IZumo, all of Japan bio—Dyn 15:339—345. Mori et al Pro—drugs for the Oral Deliver of Disodium [73] Assignee: Kyoto Pharmaceutical Industries, Cromoglycate 1988 Chem. Pharm. Bull. 36:338—344. Ltd., Kyoto, Japan Primary Examiner—Thurman K. Page Appl. N0.: Assistant Examiner—Todd D. Ware 09/202,368 Attorney, Agent, or Firm—Leydig, Voit & Mayer, Ltd. PCT Filed: Jun. 6, 1997 [57] ABSTRACT PCT No.: PCT/JP97/01974 An antirheumatic agent comprising diethyl § 371 Date: Dec. 10, 1998 L-lysylcromoglycate of the following formula § 102(e) Date: Dec. 10, 1998 NH; PCT Pub. No.: WO97/47297 [87] OCOCH(CH2)4NH2 PCT Pub. Date: Dec. 18, 1997 o OCHZCHCHZO o [30] Foreign Application Priority Data Jun. 11, 1996 [JP] Japan .................................. .. 8-149549 [51] Int. Cl.7 .......................... .. A61K 9/00; A61K 31/35; A01N 43/16 H5c2ooc o o cooczns US. Cl. ......................... .. 424/400; 514/825; 514/456 Field of Search ........................... .. 424/400; 514/825, or a nontoxic salt thereof as an active ingredient. This 514/456 compound has an anti-in?ammatory action and immuno modulating action, is absorbed by oral administration to be References Cited delivered efficiently to local sites, and is associated With feWer side effects, so that it serves Well as an antirheumatic U.S.
    [Show full text]
  • Europæisk Patentskrift
    (19) DANMARK (1°) DK/EP 2968225 T3 (12) Oversættelse af europæisk patentskrift Patent- og Varemærkestyrelsen (51) lnt.CI.: A 61 K 31/137 (2006.01) A 61 K 9/00 (2006.01) A 61 K 31/245 (2006.01) A 61 K 31/445 (2006.01) A 61 K 31/519 (2006.01) A 61 K 31/52 (2006.01) A 61 P 43/00 (2006.01) (45) Oversættelsen bekendtgjort den: 2019-05-27 (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: 2019-02-20 (86) Europæisk ansøgning nr.: 14719486.4 (86) Europæisk indleveringsdag: 2014-03-17 (87) Den europæiske ansøgnings publiceringsdag: 2016-01-20 (86) International ansøgning nr.: US2014030372 (87) Internationalt publikationsnr.: WO2014145580 (30) Prioritet: 2013-03-15 US 201361789054 P (84) Designerede stater: AL AT BE BG CH CY CZ DE DK EE ES Fl FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (73) Patenthaver: The Children's Medical Center Corporation, 55 Shattuck Street, Boston, Massachusetts 02115, USA (72) Opfinder: BERDE, Charles, 14 Doran Road, Bookline, MA 02146, USA KOHANE, Daniel S., 119 Willard Street, Newton, MA 02461, USA (74) Fuldmægtig i Danmark: AWA Denmark A/S, Strandgade 56,1401 København K, Danmark (54) Benævnelse: NEOSAXITOXINKOMBINATIONSFORMULERINGER TIL FORLÆNGET LOKALANÆSTESI (56) Fremdragne publikationer: WO-A2-98/51290 ALBERTO J. RODRIGUEZ-NAVARRO ET AL: "Potentiation of Local Anesthetic Activity of Neosaxitoxin with Bupivacaine or Epinephrine: Development of a Long-Acting Pain Blocker", NEUROTOXICITY RESEARCH, vol. 16, no. 4, 28 July 2009 (2009-07-28), pages 408-415, XP055122925, ISSN: 1029-8428, DOI: 10.1007/s12640-009- 9092-3 cited in the application Anonymous: "NCT01786655 on 2013_02_11: ClinicalTrials.gov Archive",, 11 February 2013 (2013-02-11), XP055122935, Retrieved from the Internet: URL:http://clinicaltrials.gov/archive/NCTO 1786655/2013_02_11 [retrieved on 2014-06-12] CHARLES B.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Quaternary Ammonium Compounds
    FACT SHEET: Quaternary Ammonium Compounds Quaternary ammonium compounds, also known as “quats” or “QACs,” include a number of chemicals used as sanitizers and disinfectants, including benzalkonium chloride, benzethonium chloride, cetalkonium chloride, cetrimide, cetrimonium bromide, cetylpyridinium chloride, glycidyl trimethyl, ammonium chloride, and stearalkonium chloride.[i] In general, quats cause toxic effects through all Mutagenicity routes of exposure including inhalation, Some quats have shown to be mutagenic and to ingestion, dermal application, and irrigation of damage animal DNA and DNA in human body cavities. Exposure to diluted solutions may lymphocytes at much lower levels than are result in mild irritation, while concentrated present in cleaning chemicals.[6] solutions are corrosive, causing burns to the skin and mucous Membranes. They can produce Antimicrobial Resistance systemic toxicity and can also cause allergic Genes have been discovered that mediate reactions.[2] resistance to quats. There has been an association of some of these genes with beta lactamase genes, Asthma and Allergies raising concern for a relationship between Of particular interest with regard to use as disinfectant resistance and antibiotic resistance.[7] disinfectants in the COVID-19 pandemic, quats increase the risk for asthma and allergic Reproductive Toxicity sensitization. Evidence from occupational Mice whose cages were cleaned with QACs had exposures shows increased risk of rhinitis and very low fertility rates. [8] Exposure to a common asthma
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Adverse Drug Reactions in Older Adults
    Dubrall et al. BMC Pharmacology and Toxicology (2020) 21:25 https://doi.org/10.1186/s40360-020-0392-9 RESEARCH ARTICLE Open Access Adverse drug reactions in older adults: a retrospective comparative analysis of spontaneous reports to the German Federal Institute for Drugs and Medical Devices Diana Dubrall1,2* , Katja S. Just3, Matthias Schmid1, Julia C. Stingl3 and Bernhardt Sachs2,4 Abstract Background: Older adults are more prone to develop adverse drug reactions (ADRs) since they exhibit numerous risk factors. The first aim was to analyse the number of spontaneous ADR reports regarding older adults (> 65) in the ADR database of the German Federal Institute for Drugs and Medical Devices (BfArM) and to set them in relation to i) the number of ADR reports concerning younger adults (19–65), and ii) the number of inhabitants and assumed drug-exposed inhabitants. The second aim was to analyse, if reported characteristics occurred more often in older vs. younger adults. Methods: All spontaneous ADR reports involving older or younger adults within the period 01/01/2000–10/31/2017 were identified in the ADR database. Ratios concerning the number of ADR reports/number of inhabitants and ADR reports/drug-exposed inhabitants were calculated. The reports for older (n = 69,914) and younger adults (n = 111, 463) were compared using descriptive and inferential statistics. Results: The absolute number of ADR reports involving older adults increased from 1615 (2000) up to 5367 ADR reports (2016). The age groups 76–84 and 70–79 had the highest number of ADR reports with 25 ADR reports per 100,000 inhabitants and 27 ADR reports per 100,000 assumed drug-exposed inhabitants.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Regulation of Vascular Endothelial Growth Factor Receptor-1 Expression by Specificity Proteins 1, 3, and 4In Pancreatic Cancer Cells
    Research Article Regulation of Vascular Endothelial Growth Factor Receptor-1 Expression by Specificity Proteins 1, 3, and 4in Pancreatic Cancer Cells Maen Abdelrahim,1,4 Cheryl H. Baker,4 James L. Abbruzzese,2 David Sheikh-Hamad,3 Shengxi Liu,1 Sung Dae Cho,1 Kyungsil Yoon,1 and Stephen Safe1,5 1Institute of Biosciences and Technology, Texas A&M University Health Science Center; 2Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center; 3Division of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas; 4Cancer Research Institute, M. D. Anderson Cancer Center, Orlando, Florida; and 5Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas Abstract through their specific interactions with VEGF receptors (VEGFR), Vascular endothelial growth factor receptor-1 (VEGFR1) is which are transmembrane tyrosine kinases and members of the expressed in cancer cell lines and tumors and, in pancreatic PDGF receptor gene family. and colon cancer cells, activation of VEGFR1 is linked to VEGFR1 (Flk-1), VEGFR2(Flt-1/KDR), and VEGFR3 (Flt-4) are the three major receptors for VEGF and related angiogenic factors. increased tumor migration and invasiveness.Tolfenamic acid, The former two receptors are primarily involved in angiogenesis in a nonsteroidal anti-inflammatory drug, decreases Sp protein endothelial cells, whereas VEGFR3 promotes hematopoiesis and expression in Panc-1 and L3.6pl pancreatic cancer cells, and lymphoangiogenesis (2, 3, 7, 8). VEGFR2 plays a critical role in this was accompanied by decreased VEGFR1 protein and angiogenesis; homozygous knockout mice were embryonic lethal mRNA and decreased luciferase activity on cells transfected [gestation day (GD) 8.5–9.0] and this was associated with the with constructs (pVEGFR1) containing VEGFR1 promoter failure to develop blood vessels (9).
    [Show full text]
  • Quaternary Ammonium Compounds
    FT-619502 Quaternary ammonium compounds Products Description Name : BenzyldimethylhexadecylAmmoniu m Chloride Catalog Number : 619502, 100g 16-BAC ; Cetalkonium chloride; N-hexadecyl-N,N-dimethyl Benzenemethaminium, Chloride; cloruro de Structure : CAS: [122-18-9]; cetalconio; Chlorure de cetalkonium Benzyldimethylhexadecylammonium chloride; Benzyl n-hexadecyl Molecular Weight : MW= 396.1 dimethylammonium chloride; Cetol; Benzyldimethylhexadecylammonium chloride, hydrate; N-Hexadecyl- N,N-dimethylbenzenemethanaminium chloride; Alkyl C-16 Properties: Freely soluble benzyldimethyl ammonium chloride; pH : 6.0 - 8.5 (10% sol.) Corrosive Avoid shock and frictions S26-45-60-61 Storage: Room temperature (Z) Technical and Scientific Information General description and applications Quaternary ammonium compounds are any of a group of ammonium salts in which organic radicals have been substituted for all four hydrogens of the original ammonium cation. They has a central nitrogen atom which is joined to four organic radicals and one acid radical. The organic radicals may be alkyl, aryl, or aralkyl, and the nitrogen can be part of a ring system. They are prepared by treatment of an amine with an alkylating agent. They show a variety of physical, chemical, and biological properties and most compounds are soluble in water and strong electrolytes. Such compounds include: Benzalkonium Chloride ( CAS RN: 8001-54-5) Benzethonium Chloride CAS 121-54-0 Cetalkonium Chloride( CAS 122-18-9) Cetrimide ( CAS 8044-71-1) Cetrimonium Bromide ( CAS 57-09-0) Cetylpyridinium
    [Show full text]
  • Clinical Trial Protocol: BPS-314D-MR-PAH-302
    Clinical Trial Protocol: BPS-314d-MR-PAH-302 Study Title: A multicenter, double-blind, randomized, placebo-controlled, Phase 3 study to assess the efficacy and safety of oral BPS-314d-MR added-on to treprostinil, inhaled (Tyvaso®) in subjects with pulmonary arterial hypertension Study Number: BPS-314d- MR-PAH-302 Study Phase: 3 Product Name: Beraprost Sodium 314d Modified Release IND Number: 111,729 Indication: Treatment of Pulmonary Arterial Hypertension Investigators: Multicenter Sponsor: Lung Biotechnology Inc. Sponsor Contact: Medical Monitor: Date Original Protocol: 16 April 2013 Amendment 1: 17 December 2013 Amendment 2 15 October 2014 GCP Statement: This study will be conducted in compliance with the protocol, Good Clinical Practice (GCP) and applicable regulatory requirements. Confidentiality Statement The concepts and information contained herein are confidential and proprietary and shall not be disclosed in whole or part without the express written consent of Lung Biotechnology Inc. © 2014 Lung Biotechnology Inc. Beraprost Sodium 314d Modified Release Lung Biotechnology Inc. Clinical Trial Protocol: BPS-314-d-MR-PAH 302 15 October 2014 LIST OF CONTACTS Study Sponsor: Lung Biotechnology Inc. 1040 Spring Street Silver Spring, Maryland 20910 United States Phone: 301-608-9292 Fax: 301-589-0855 Sponsor Contact: Medical Monitor: SAE Reporting: CONFIDENTIAL Page 2 of 75 Beraprost Sodium 314d Modified Release Lung Biotechnology Inc. Clinical Trial Protocol: BPS-314-d-MR-PAH 302 15 October 2014 SYNOPSIS Sponsor: Lung Biotechnology Inc.
    [Show full text]